title: Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
authors.affiliation: Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy. ga.buda@libero.it
authors.forename: Gabriele
authors.initials: G
authors.lastname: Buda
authors.forename: Enrico
authors.initials: E
authors.lastname: Orciuolo
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Nadia
authors.initials: N
authors.lastname: Cecconi
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D011719:Pyrazines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation
chemical_list: D001897:Boronic Acids; D008081:Liposomes; D011719:Pyrazines; D000069286:Bortezomib; D004317:Doxorubicin